Creative Planning reduced its stake in shares of The Clorox Company (NYSE:CLX – Get Rating) by 6.1% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 27,057 shares of the company’s stock after selling 1,746 shares during the quarter. Creative Planning’s holdings in Clorox were worth $3,474,000 as of its most recent SEC filing.
Other institutional investors also recently added to or reduced their stakes in the company. Heritage Financial Services LLC bought a new position in Clorox in the second quarter worth about $30,000. Carolinas Wealth Consulting LLC raised its stake in shares of Clorox by 10,476.2% during the 2nd quarter. Carolinas Wealth Consulting LLC now owns 13,749 shares of the company’s stock worth $30,000 after acquiring an additional 13,619 shares in the last quarter. Curi Wealth Management LLC lifted its position in Clorox by 64.5% during the second quarter. Curi Wealth Management LLC now owns 227 shares of the company’s stock valued at $32,000 after acquiring an additional 89 shares during the last quarter. Massmutual Trust Co. FSB ADV boosted its stake in Clorox by 65.8% in the third quarter. Massmutual Trust Co. FSB ADV now owns 252 shares of the company’s stock valued at $32,000 after acquiring an additional 100 shares in the last quarter. Finally, Charter Oak Capital Management LLC acquired a new stake in Clorox in the second quarter valued at approximately $36,000. Institutional investors own 79.12% of the company’s stock.
Clorox Price Performance
NYSE:CLX opened at $140.98 on Wednesday. The firm’s fifty day moving average is $145.51 and its two-hundred day moving average is $143.11. The firm has a market cap of $17.39 billion, a price-to-earnings ratio of 43.25, a PEG ratio of 2.98 and a beta of 0.31. The Clorox Company has a one year low of $120.50 and a one year high of $175.93. The company has a debt-to-equity ratio of 4.99, a quick ratio of 0.50 and a current ratio of 0.88.
Clorox Announces Dividend
The company also recently declared a quarterly dividend, which will be paid on Friday, February 10th. Investors of record on Wednesday, January 25th will be issued a dividend of $1.18 per share. This represents a $4.72 dividend on an annualized basis and a yield of 3.35%. The ex-dividend date of this dividend is Tuesday, January 24th. Clorox’s dividend payout ratio (DPR) is presently 144.79%.
Wall Street Analyst Weigh In
CLX has been the subject of several analyst reports. JPMorgan Chase & Co. increased their price objective on Clorox from $126.00 to $135.00 and gave the company an “underweight” rating in a report on Friday, January 13th. Evercore ISI initiated coverage on Clorox in a report on Monday, October 17th. They issued an “underperform” rating for the company. Wells Fargo & Company lifted their target price on shares of Clorox from $125.00 to $135.00 and gave the stock an “underweight” rating in a research note on Tuesday, January 3rd. UBS Group upped their price target on shares of Clorox from $119.00 to $129.00 and gave the company a “sell” rating in a research note on Wednesday, November 2nd. Finally, DA Davidson lifted their price objective on shares of Clorox from $124.00 to $155.00 and gave the stock a “neutral” rating in a research note on Wednesday, November 2nd. Nine equities research analysts have rated the stock with a sell rating, four have given a hold rating and one has given a buy rating to the stock. According to MarketBeat.com, Clorox has an average rating of “Reduce” and an average target price of $136.92.
The Clorox Co engages in the manufacture and marketing of consumer and professional products. It operates through the following business segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment consists of cleaning products, professional products and vitamins, minerals and supplements mainly marketed and sold in the United States.
- Get a free copy of the StockNews.com research report on Clorox (CLX)
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- Is the Pain Over for Baudax Bio Investors after a 70% Spike?
- Will Rocket Lab’s First U.S. Launch Send Stock Into Stratosphere?
- Is It Time To Get Aggressive With Defense Stocks?
Receive News & Ratings for Clorox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox and related companies with MarketBeat.com's FREE daily email newsletter.